Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   50 Trials   3648 News 


«12...1314151617181920212223...5960»
  • ||||||||||  Review, Journal:  Pituitary Incidentalomas: Best practices and Looking Ahead. (Pubmed Central) -  Oct 22, 2022   
    For incidentally-detected lactotroph, somatotroph and corticotroph adenomas, disease-specific management guidelines apply. Prospective studies are needed to enhance our understanding of the long-term course and response to treatment.
  • ||||||||||  Review, Journal, HEOR:  Evaluating the Impact of Acromegaly on Quality of Life. (Pubmed Central) -  Oct 18, 2022   
    We recommend that a patient-centered approach should be considered in treatment decisions, integrating conventional biochemical outcomes, tumor control, comorbidities, treatment complications, and PROMs, including QoL measures. This more integrated approach seems effective in treating comorbidities and improving patient-reported outcomes and is critical, as many patients do not achieve biochemical or tumor control and comorbidities, impairment in QoL may not remit even when full biochemical control is achieved.
  • ||||||||||  cabergoline / Generic mfg.
    Retrospective data, Journal:  Effect of Cabergoline Treatment on Disease Control in Acromegaly Patients. (Pubmed Central) -  Oct 14, 2022   
    Immunopositivity for prolactin in adenoma tissue was found in three patients with IGF-I normalization. Cabergoline therapy is effective in the normalization of IGF-I levels even in normoprolactinemic acromegaly patients when IGF-I levels are mildly or moderately elevated during SRL therapy.
  • ||||||||||  Review, Journal:  Patient journey experiences may contribute to improve healthcare for patients with rare endocrine diseases. (Pubmed Central) -  Oct 14, 2022   
    Offering access to adequate patient information on their disease, treatments and outcome, helps to adapt to living with a chronic disease and what to expect in the future, contemplating the impact of a disease on patients' everyday life, not only clinical outcome but also social, financial, educational, family and leisure issues is desirable; this facilitates more realistic expectancies for patients, and can even lead to a reduction in health costs. Patient empowerment with patient-centred approaches to these complex or chronic diseases should be contemplated more and more, for the benefit of those affected, but also for the entire health system.
  • ||||||||||  Journal:  The acromegaly lipodystrophy. (Pubmed Central) -  Oct 7, 2022   
    Understanding the pathophysiology of the lipodystrophy and how acromegaly therapies differentially reverse its features may be important to optimizing the long-term outcome for patients with this disease. This perspective describes evidence in support of this acromegaly lipodystrophy model and its relevance to acromegaly pathophysiology and the treatment of patients with acromegaly.
  • ||||||||||  Signifor LAR (pasireotide long acting release) / Recordati
    Journal:  Clinical, hormonal and pathomorphological markers of somatotroph pituitary neuroendocrine tumors predicting the treatment outcome in acromegaly. (Pubmed Central) -  Oct 4, 2022   
    This study aimed to assess whether clinical, biochemical, imaging and pathological characteristics can predict surgical remission and response to first-generation somatostatin receptor ligands (SRLs) and pasireotide-LAR in acromegaly...Fasting GH concentration <36.6 µg/L and DG tumor turned out to be independent predictors of good response to first-generation SRLs (OR=0.96, p=0.06 and OR=10.68, p=0.002, respectively). Younger age at diagnosis, male sex, lower GH, IGF-1 and PRL concentrations, smaller tumor size at diagnosis as well as positive α-SU staining, lower Ki-67 index and DG tumors predicted better treatment outcome in acromegaly patients.
  • ||||||||||  Journal:  Reduced irisin levels in patients with acromegaly. (Pubmed Central) -  Oct 2, 2022   
    Single nucleotide polymorphisms (SNPs) of FNDC5 have no independent effects on circulating irisin levels under somatostatin ligand action. Endocrine muscle functions also seem to be regulated by somatostatin action, which requires further studies.
  • ||||||||||  Challenges in the current treatment of acromegaly (Rhône 2) -  Oct 1, 2022 - Abstract #ENEA2022ENEA_291;    
    Despite identifying rare diseases using real-world data is challenging, this study showed that robust validity testing may yield the identification of accurate coding algorithms. Sponsored by AMRYT
  • ||||||||||  Clinical manifestations of musculoskeletal complications of acromegaly. () -  Oct 1, 2022 - Abstract #ENEA2022ENEA_259;    
    (100%), swelling of the joints (93.3%), expansion of the distal phalanges (92%), puffiness of the face (90.6%), prognathism (80%) and diastema (72%), limitation mobility of the knee joints (70%) and polyarthralgia (66%). X-ray, being one of the available methods for diagnosing MC of acromegaly, allowed detection in 92% of patients of deformity of the phalanges of the hands, feet, thickening skull bones (92.7%) and signs of osteoporosis of the spine (90%); 80% expansion of the periarticular space and deformation of the lower jaw, in sinus enlargement (84%) and signs of femoral osteoporosis (80.7%).
  • ||||||||||  Clinical characterization of insulin resistance in patients with different pituitary adenomas () -  Oct 1, 2022 - Abstract #ENEA2022ENEA_254;    
    Discussion.Retrospective analysis of patients with different pituitary adenomas showed that more often the manifestation of the disease was headache(45.7%), hypertension(8.6%),excessive sweet cravings(6.2%) and dysmenorrhea(4.9%). Less frequent presentation of the disease was vision problems(2.4%) and amenorrhea(1.2%).Of the risk factors for the disease, the most common were acute viral infection(45.7%) and hepatitis(18.5%).
  • ||||||||||  Optimization of medical therapy in patients with acromegaly () -  Oct 1, 2022 - Abstract #ENEA2022ENEA_223;    
    On the contrary,patients with RHA were characterized by an early age of diagnosis,large sizes of pituitary adenoma with extrasellar distribution and invasive growth. The most significant independent signs associated with % decrease in the level of IGF-1 after 3months of SA1 treatment are: 1.duration of effective SA1 MT (months) (beta=0.56; p=0.034); 2.severity of expression of the 2nd subtype of SSR (beta=0.42; p=0.011); 3.difference in expression scores of the 2nd&5th SSR subtypes (beta=0.39; p=0.015).
  • ||||||||||  Tumor volume assessment in consecutive newly-diagnosed patients with acromegaly- evaluation of two methods () -  Oct 1, 2022 - Abstract #ENEA2022ENEA_205;    
    Surprisingly, tumor volume estimation using both methods did not predict the outcomes of the surgery in the univariate logistic regression (p=0.117) Discussion Both methods show a strong correlation between each other and with median tumor diameter- therefore their use may be reliable. Surprisingly, tumor volume did not predict the neurosurgery outcomes in our cohort of patients.
  • ||||||||||  Somavert (pegvisomant) / Pfizer
    The immune cell profiling in acromegalic patients. Preliminary results from a case-control study () -  Oct 1, 2022 - Abstract #ENEA2022ENEA_201;    
    Significant differences in monocytes number and subpopulations were observed, with a decreased total monocytes count (cells/μL) [128.0 (51.0-243.0) vs 339 (280.2-414.6), p<0.001], a lower percentage of classical monocytes, % [83.6 (79.1-88.0) vs 87.8 (84.9-91.3), p=0.023] and intermediate monocytes, % [2.4 (0.3-4.4) vs 7.3 (5.5-10.4) p<0.001] and higher percentage of non-classical monocytes, % [11.3 (10.4-14.3) vs 1.7 (1.0-3.3), p<0.001], as compared with controls. Acromegalic patients also showed a decreased total number of NK (cells/μL) [121.6 (62.0-261.3) vs 333.7 (253.4-485.4), p<0.001] with a lower percentage of NK CD56bright, % [3.44 (1.5-5.7) vs 7.8 (6.9-10.2), p=0.001] and a higher percentage of NK CD56dim, % [97.1 (93.5-97.8) vs 91.3 (88.2-92.8), p=0.003] than in controls.